Surgery vs first chemotherapy for stomach signet ring cancer
Part of Cancer, Digestive system clinical trials.
This trial compares doing surgery first versus starting chemotherapy first for people with resectable signet ring–type stomach cancer. It aims to find which approach works better to cure the cancer and prevent spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach (or the junction of the esophagus and stomach) cancer that is proven as signet ring type on biopsy
- Your cancer stage is IB, II, or III, and doctors think it can be removed with curative intent
- There is no spread to distant organs and no cancer coating on the belly (peritoneal carcinomatosis) seen on a look-in-the-abdomen procedure before treatment
- You can do daily activities with limited help (performance status 2 or less) and you are age 18–80
- Your blood and organ tests are good enough for treatment (kidney, liver/bilirubin, blood counts, albumin, clotting)
- You have not had chemotherapy or radiation for stomach cancer before, and you are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
This trial compares two chemotherapy combinations given before surgery for stomach cancer that has not spread. The goal is to see which treatment works better and to shrink the tumor before removal.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
This trial tests whether using a blood test (Signatera) to guide treatment can safely reduce the amount of chemotherapy after surgery for stomach or esophagus cancer. The goal is to see if less treatment is just as effective, based on whether cancer DNA is still detectable in your blood.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
Hear when a new Signet Ring Cell Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.